Business
Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars
MEDIA RELEASE Pyzchiva® first ustekinumab biosimilar in Europe commercially available in pre-filled pen (autoinjector), offering improved self-administration experience for better treatment adherence and quality of life [1-10] Autoinjector includes unique features to improve comfort, independence and convenience for patients with chronic inflammatory diseases [1-10] Launch strengthens Sandoz biosimilar leadership position in immunology and commitment to patient-centric innovation Basel, May 21,
About this update from Sandoz Group Ltd
[{"type":"image","alt":"Sandoz Group","displaySize":"","headline":null,"caption":"Sandoz Group","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":41,"url":"https://media.zenfs.com/en/globenewswire.com/f12e92daa0852ddf107832c313b07d25"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qaCYsKqoASJVSMd1vUCp9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/f12e92daa0852ddf107832c313b07d25","width":300,"height":41}},"lazy":false},{"type":"text","content":"MEDIA RELEASE","length":13,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Pyzchiva® first ustekinumab biosimilar in Europe commercially available in pre-filled pen (autoinjector), offering improved self-administration experience for better treatment adherence and quality of life [1-10]","length":212,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":212,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Autoinjector includes unique features to improve comfort, independence and convenience for patients with chronic inflammatory diseases [1-10]","length":141,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":141,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Launch strengthens Sandoz biosimilar leadership position in immunology and commitment to patient-centric innovation","length":115,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":115,"olType":false},{"type":"text","content":"Basel, May 21, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced the European launch of its Pyzchiva®* (ustekinumab) autoinjector.[1-2] This is the first ustekinumab biosimilar in Europe commercially available in an autoinjector. Developed and registered by Samsung Bioepis, Pyzchiva® is approved for the treatment of adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and pediatric plaque psoriasis for patients aged six years and older, weighing over 60 kg.[1]","length":536,"tagName":"p"},{"type":"text","content":"The Pyzchiva® autoinjector supports a more comfortable self-administration experience [1-10] with accurate automatic dosing [1,3,4], less frequent injection pain [1,9,10], a compact design [1,3,4,6,7], and flexible storage options [1], offering the potential for ...